July 2011

Merck to cut 12K jobs

Friday, July 29, 2011

Merck plans to slash thousands more jobs by late 2015 to wring out additional annual cost savings of up to $1.5 billion that can be plowed back into research and deal making, according to Reuters.

[Read More]

Micell completes enrollment for DESSOLVE II study

Friday, July 29, 2011

Micell Technologies has completed patient enrollment in its DESSOLVE II CE Mark clinical study of the MiStentR drug-eluting coronary stent system. The MiStent DES is an ultra-thin drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating formulation. Enrollment of 183 patients across 26 study centers throughout Europe and New Zealand was accomplished ahead of schedule.

[Read More]

Lutonix enrolls first patient in LEVANT 2 trial

Friday, July 29, 2011

Lutonix has enrolled its first patient in the LEVANT 2 clinical trial, a global, multi-center, randomized trial evaluating the safety and efficacy of the Moxy(TM) Drug Coated Balloon compared to a standard angioplasty balloon for the treatment of peripheral arterial disease (PAD).  The first case was performed at St. John’s Hospital in Springfield, Ill., by Dr. Jeff Goldstein.

[Read More]

FDA approves Wiskott Aldrich gene therapy trial

Friday, July 29, 2011

The FDA approved the launching in the U.S. of a clinical trial for gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome (WAS). After its implementation in Paris and London, this trial based on preclinical research performed at Genethon (Evry, France) which also manufactures the GMP gene therapy product, is now going to be launched in Boston. It’s one of the first international clinical trials using a gene therapy treatment for a rare disease.

[Read More]

EMA recommends INCIVO for hepatitis C virus

Friday, July 29, 2011

Tibotec Virco-Virology BVBA, part of Janssen Pharmaceutical, reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the approval of INCIVO (telaprevir), a direct acting antiviral (DAA) for the treatment of chronic genotype-1 hepatitis C virus (HCV), in combination with pegylated-interferon and ribavirin, the previously accepted standard of care.

[Read More]

GSK CEO predicts R&D success

Friday, July 29, 2011

GlaxoSmithKline CEO Andrew Witty said the pharmaceutical industry would contract in coming years and that the survivors would be those companies that solved the “equation” of how to squeeze the most profit from every dollar spent on R&D, according to the Philadelphia Inquirer.

[Read More]